Methylation of nucleolar and coiled-body phosphoprotein 1 is associated with the mechanism of tumorigenesis in hepatocellular carcinoma

Duan,Xuefei; Zhang,Jinqian; Liu,Shunai; Zhang,Mengran; Wang,Qi; Cheng,Jun

doi:10.3892/or.2013.2676

Methylation of nucleolar and coiled-body phosphoprotein 1 is associated with the mechanism of tumorigenesis in hepatocellular carcinoma

Authors:
- Xuefei Duan
- Jinqian Zhang
- Shunai Liu
- Mengran Zhang
- Qi Wang
- Jun Cheng
View Affiliations

Affiliations: Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P.R. China
Published online on: August 20, 2013 https://doi.org/10.3892/or.2013.2676
Pages: 2220-2228

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nucleolar and coiled-body phosphoprotein 1 (NOLC1) plays an essential role in the synthesis of rRNA and the biosynthesis of ribosomes. Previous studies suggest that NOLC1 is crucial for normal cell growth, and plays a role in the regulation of tumorigenesis of nasopharyngeal carcinoma (NPC) and demonstrate that both NOLC1 and tumor protein 53 work synergistically to activate the MDM2 promoter in NPC cells. Yet, the functioning of NOLC1 in liver cancer remains unknown. The aim of the present study was to understand how the NOLC1 gene is regulated in liver carcinogenesis. In this study, we showed that NOLC1 was silenced or downregulated in liver tumor tissues when compared with that in the matched non-cancer tissues. In addition, human hepatoma cells weakly expressed NOLC1, whereas cultured human normal liver cell lines expressed abundant levels. The hypermethylation status in the promoter CpG1 start region appeared to be correlated with the NOLC1 expression levels in liver cell lines or liver normal and tissue specimens. We found that four CpG dinucleotides were located at the CpG1 start region. Further molecular analysis of mutagenesis indicated that the four CpG dinucleotides play a role in the promoter activity of the NOLC1 gene. The expression of NOLC1 and DNA methylation of its promoter affected cell proliferation and apoptosis. The expression of NOLC1 in hepatoma cell lines was restored following exposure to the demethylation agent, 5-azacytidine. Low expression of NOLC1 in hepatoma cell lines and liver cancer tissues was associated with cyclin D3. In conclusion, our study demonstrated that DNA methylation is a key mechanism of silenced NOLC1 expression in human hepatocellular carcinoma cells, and NOLC1 gene hypermethylation of the four CpG dinucleotides is a potential biomarker for hepatocellular carcinoma.

View Figures

View References

1	Beasley RP, Hwang LY, Lin CC and Chien CS: Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 2:1129–1133. 1981. View Article : Google Scholar : PubMed/NCBI
2	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
3	Tischoff I and Tannapfe A: DNA methylation in hepatocellular carcinoma. World J Gastroenterol. 14:1741–1748. 2008. View Article : Google Scholar : PubMed/NCBI
4	Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI
5	Riggs AD and Pfeifer GP: X-chromosome inactivation and cell memory. Trends Genet. 8:169–174. 1992. View Article : Google Scholar : PubMed/NCBI
6	Yang Q, Cheng J, Liu Y, Hong Y, Wang JJ and Zhang SL: Cloning and identification of NS5ATP2 gene and its spliced variant transactivated by hepatitis C virus non-structural protein 5A. World J Gastroenterol. 10:1735–1739. 2004.
7	Meier UT: Comparison of the rat nucleolar protein nopp140 with its yeast homolog SRP40. Differential phosphorylation in vertebrates and yeast. J Biol Chem. 271:19376–19384. 1996.PubMed/NCBI
8	Meier UT and Blobel G: Nopp140 shuttles on tracks between nucleolus and cytoplasm. Cell. 70:127–138. 1992. View Article : Google Scholar : PubMed/NCBI
9	Gao XS, Wang Q, Li W, Yang B, Song H, Ju W, Liu SA and Cheng J: Identification of nucleolar and coiled-body phosphoprotein 1 (NOLC1) minimal promoter regulated by NF-κB and CREB. BMB Rep. 44:70–75. 2011.PubMed/NCBI
10	Meier UT and Blobel G: A nuclear localization signal binding protein in the nucleolus. J Cell Biol. 111:2235–2245. 1990. View Article : Google Scholar : PubMed/NCBI
11	Miau LH, Chang CJ, Tsai WH and Lee SC: Identification and characterization of a nucleolar phosphoprotein. Nopp140, as a transcription factor. Mol Cell Biol. 17:230–239. 1997.PubMed/NCBI
12	Hwang YC, Lu TY, Huang DY, Kuo YS, Kao CF, Yeh NH, Wu HC and Lin CT: NOLC1, an enhancer of nasopharyngeal carcinoma progression, is essential for TP53 to regulate MDM2 expression. Am J Pathol. 175:342–354. 2009. View Article : Google Scholar : PubMed/NCBI
13	Pai CY, Chen HK, Sheu HL and Yeh NH: Cell-cycle-dependent alterations of a highly phosphorylated nucleolar protein p130 are associated with nucleologenesis. J Cell Sci. 108:1911–1920. 1995.PubMed/NCBI
14	Lin CT, Lin CR, Tan GK, Chen W, Dee AN and Chan WY: The mechanism of Epstein-Barr virus infection in nasopharyngeal carcinoma cells. Am J Pathol. 150:1745–1756. 1997.PubMed/NCBI
15	Wu HC and Lin CT: Association of heterotrimeric GTP binding regulatory protein (Go) with mitosis. Lab Invest. 71:175–181. 1994.PubMed/NCBI
16	Jiang M and Milner J: Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev. 17:832–837. 2003. View Article : Google Scholar : PubMed/NCBI
17	Jiang M, Rubbi CP and Milner J: Gel-based application of siRNA to human epithelial cancer cells induces RNAi-dependent apoptosis. Oligonucleotides. 14:239–248. 2004. View Article : Google Scholar : PubMed/NCBI
18	Kim YK, Lee WK, Jin YN, Lee KJ, Jeon HS and Yu YG: Doxorubicin binds to un-phosphorylated form of hNopp140 and reduces protein kinase CK2-dependent phosphorylation of hNopp140. J Biochem Mol Biol. 39:774–781. 2006. View Article : Google Scholar : PubMed/NCBI
19	Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R and Nakamura Y: SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 6:731–740. 2004. View Article : Google Scholar : PubMed/NCBI
20	Ford J, Jiang M and Milner J: Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 65:10457–10463. 2005. View Article : Google Scholar : PubMed/NCBI
21	Li H, Bergeron L, Cryns V, Pasternack MS, Zhu H, Shi L, Greenberg A and Yuan J: Activation of caspase-2 in apoptosis. J Biol Chem. 272:21010–21017. 1997. View Article : Google Scholar : PubMed/NCBI
22	Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT: MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012. View Article : Google Scholar : PubMed/NCBI
23	Liu HY, Dong HJ, Robertson K and Liu C: DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma. Am J Pathol. 178:652–661. 2011. View Article : Google Scholar
24	Herath NI, Leggett BA and MacDonald GA: Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol. 21:15–21. 2006. View Article : Google Scholar : PubMed/NCBI
25	Li HP, Leu YW and Chang YS: Epigenetic changes in virus-associated human cancers. Cell Res. 15:262–271. 2005. View Article : Google Scholar : PubMed/NCBI
26	Herceg Z: Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis. 22:91–103. 2007. View Article : Google Scholar : PubMed/NCBI
27	Adrien LR, Schlecht NF, Kawachi N, Smith RV, Brandwein-Gensler M, Massimi A, Chen S, Prystowsky MB, Childs G and Belbin TJ: Classification of DNA methylation patterns in tumor cell genomes using a CpG island microarray. Cytogenet Genome Res. 114:16–23. 2006. View Article : Google Scholar : PubMed/NCBI
28	Lund AH and van Lohuizen M: Epigenetics and cancer. Genes Dev. 18:2315–2335. 2004. View Article : Google Scholar : PubMed/NCBI
29	Sparmann A and van Lohuizen M: Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 6:846–856. 2006. View Article : Google Scholar : PubMed/NCBI
30	Lo SJ, Lee CC and Lai HJ: The nucleolus: reviewing oldies to have new understandings. Cell Res. 16:530–538. 2006. View Article : Google Scholar : PubMed/NCBI
31	Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res. 61:3225–3229. 2001.PubMed/NCBI
32	Lin J, Jinno S and Okayama H: Cdk6-cyclin D3 complex evades inhibition by inhibitor proteins and uniquely controls cell’s proliferation competence. Oncogene. 20:2000–2009. 2001.PubMed/NCBI
33	Rao CN, Liu YY, Peavey CL and Woodley DT: Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch Biochem Biophys. 317:311–314. 1995. View Article : Google Scholar : PubMed/NCBI
34	Sprecher CA, Kisiel W, Mathewes S and Foster DC: Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA. 91:3353–3357. 1994. View Article : Google Scholar
35	Rao CN, Cook B, Liu Y, Chilukuri K, Stack MS, Foster DC, Kisiel W and Woodley DT: HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int J Cancer. 76:749–756. 1998. View Article : Google Scholar : PubMed/NCBI
36	Rao CN, Mohanam S, Puppala A and Rao JS: Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. Biochem Biophys Res Commun. 255:94–98. 1999. View Article : Google Scholar : PubMed/NCBI
37	Wong CM, Ng YL, Lee JM, Wong CC, Cheung OF, Chan CY, Tung EK, Ching YP and Ng IO: Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology. 45:1129–1138. 2007. View Article : Google Scholar : PubMed/NCBI
38	Kim H, Jen J, Vogelstein B and Hamilton SR: Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol. 145:148–156. 1994.PubMed/NCBI
39	Oliveira C, Seruca R, Seixas M and Sobrinho-Simões M: The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different ‘target genes’: a study of the TGFβ RII, IGFII R, and BAX genes. Am J Pathol. 153:1211–1219. 1998.PubMed/NCBI
40	Park JH, Cho SB, Lee WS, Park CH, Joo YE, Kim HS, Choi SK, Rew JS, Lee JH and Kim SJ: Methylation pattern of DNA repair genes and microsatellite instability in hepatocellular carcinoma. Korean J Gastroenterol. 48:327–336. 2006.(In Korean).
41	Matsukura S, Soejima H, Nakagawachi T, Yakushiji H, Ogawa A, Fukuhara M, Miyazaki K, Nakabeppu Y, Sekiguchi M and Mukai T: CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. Br J Cancer. 88:521–529. 2003. View Article : Google Scholar : PubMed/NCBI
42	Wang L, Bani-Hani A, Montoya DP, Roche PC, Thibodeau SN, Burgart LJ and Roberts LR: hMLH1 and hMSH2 expression in human hepatocellular carcinoma. Int J Oncol. 19:567–570. 2001.PubMed/NCBI